More than half of the genes identified in our previous study of gene regulation by EGFR blockade were significantly modulated upon ErbB2 inhibition in ErbB2-positive cancer cells as well suggesting highly shared oncogenic pathways. The gene discussed is EGFR; the disease is cancer.